ES2651287T3 - Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral - Google Patents

Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral Download PDF

Info

Publication number
ES2651287T3
ES2651287T3 ES13179144.4T ES13179144T ES2651287T3 ES 2651287 T3 ES2651287 T3 ES 2651287T3 ES 13179144 T ES13179144 T ES 13179144T ES 2651287 T3 ES2651287 T3 ES 2651287T3
Authority
ES
Spain
Prior art keywords
angiogenesis
vascularization
stimulation
inhibition
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13179144.4T
Other languages
English (en)
Inventor
Stefanie Dimmeler
Carmen Urbich
Andreas Zeiher
Angelika Bonauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T2cure GmbH
Original Assignee
T2cure GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T2cure GmbH filed Critical T2cure GmbH
Application granted granted Critical
Publication of ES2651287T3 publication Critical patent/ES2651287T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de una molécula antisentido para la preparación de una composición farmacéutica para el tratamiento o para la prevención del síndrome coronario agudo, infarto de miocardio, ictus, cardiomiopatía, enfermedad cardiaca isquémica crónica, oclusión de arterias periféricas o infarto isquémico, siendo la molécula antisentido complementaria a miR-92.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10

Claims (1)

  1. imagen1
ES13179144.4T 2007-10-30 2008-10-30 Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral Active ES2651287T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007052114A DE102007052114B4 (de) 2007-10-30 2007-10-30 Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
DE102007052114 2007-10-30

Publications (1)

Publication Number Publication Date
ES2651287T3 true ES2651287T3 (es) 2018-01-25

Family

ID=40375407

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13179144.4T Active ES2651287T3 (es) 2007-10-30 2008-10-30 Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral
ES08844273.6T Active ES2618203T3 (es) 2007-10-30 2008-10-30 Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08844273.6T Active ES2618203T3 (es) 2007-10-30 2008-10-30 Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral

Country Status (16)

Country Link
US (4) US8258113B2 (es)
EP (3) EP2217704B1 (es)
JP (4) JP5898843B2 (es)
CA (1) CA2704290C (es)
CY (2) CY1120360T1 (es)
DE (1) DE102007052114B4 (es)
DK (2) DK2217704T3 (es)
ES (2) ES2651287T3 (es)
HR (2) HRP20170346T1 (es)
HU (2) HUE031559T2 (es)
LT (2) LT2684955T (es)
NO (1) NO2684955T3 (es)
PL (2) PL2684955T3 (es)
PT (2) PT2217704T (es)
SI (2) SI2684955T1 (es)
WO (1) WO2009056116A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP4082551A1 (en) 2006-08-08 2022-11-02 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US20130302293A1 (en) * 2010-11-11 2013-11-14 Keith A. Webster Compositions, cells, kits and methods for autologous stem cell therapy
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
DK3354734T3 (da) 2012-06-21 2020-06-29 Miragen Therapeutics Inc Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
EP2759595B1 (en) * 2013-01-24 2016-09-14 Pierre Fabre Médicament S.A.S. Composition comprising an encapsulated antagomir
AU2014233115B2 (en) 2013-03-15 2019-08-01 MiRagen Therapeutics, Inc. Bridged bicyclic nucleosides
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US20160122762A1 (en) * 2014-10-27 2016-05-05 University Of Iowa Research Foundation Methods of treating atherosclerosis
US9885042B2 (en) * 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
CN107586784B (zh) * 2016-07-08 2020-08-25 田小利 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
US11674141B2 (en) * 2018-02-28 2023-06-13 National University Corporation Tokyo Medical And Dental University Ischemic-lesion-site-specific gene therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
EP2290072B1 (en) * 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
WO2006133022A2 (en) * 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2008008430A2 (en) * 2006-07-13 2008-01-17 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008070082A2 (en) * 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2009004632A2 (en) * 2007-07-05 2009-01-08 Yeda Research And Development Co. Ltd. Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
BRPI0813527A2 (pt) * 2007-07-18 2014-12-30 Univ Colorado Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Also Published As

Publication number Publication date
US20100324118A1 (en) 2010-12-23
CA2704290A1 (en) 2009-05-07
SI2217704T1 (sl) 2017-05-31
US20150018407A1 (en) 2015-01-15
NO2684955T3 (es) 2018-02-03
US9862949B2 (en) 2018-01-09
EP2684956B1 (de) 2017-08-23
US20120322856A1 (en) 2012-12-20
JP2011500858A (ja) 2011-01-06
EP2217704A1 (de) 2010-08-18
DE102007052114B4 (de) 2011-01-05
PL2217704T3 (pl) 2017-06-30
US8258113B2 (en) 2012-09-04
US9279123B2 (en) 2016-03-08
CA2704290C (en) 2018-05-15
EP2217704B1 (de) 2016-12-07
WO2009056116A1 (de) 2009-05-07
JP2016199565A (ja) 2016-12-01
DK2217704T3 (en) 2017-03-13
HUE037494T2 (hu) 2018-08-28
CY1120226T1 (el) 2018-12-12
CY1120360T1 (el) 2019-07-10
ES2618203T3 (es) 2017-06-21
JP2018083817A (ja) 2018-05-31
EP2684955B1 (de) 2017-09-06
DK2684955T3 (en) 2017-12-18
LT2684955T (lt) 2017-12-27
PT2684955T (pt) 2017-12-13
LT2217704T (lt) 2017-04-10
PL2684955T3 (pl) 2018-05-30
EP2684955A1 (de) 2014-01-15
HRP20171874T1 (hr) 2018-01-12
JP5898843B2 (ja) 2016-04-06
HUE031559T2 (hu) 2017-07-28
JP2014196317A (ja) 2014-10-16
US20160237433A1 (en) 2016-08-18
SI2684955T1 (en) 2018-01-31
DE102007052114A1 (de) 2009-05-07
EP2684956A1 (de) 2014-01-15
HRP20170346T1 (hr) 2017-04-21
PT2217704T (pt) 2017-03-15
US8912158B2 (en) 2014-12-16

Similar Documents

Publication Publication Date Title
ES2651287T3 (es) Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
AR066168A1 (es) Formulaciones galenicas de compuestos organicos
NI201000034A (es) Activadores de guanilato ciclasas solubles.
ECSP19001018A (es) Moduladores del receptor adrenérgico beta -3 útiles para el tratamiento o prevención de trastornos relacionados con los mismos
CO5621286A2 (es) Combinacion de un inhibidor de dpp iv y un compuesto cardiovascular
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
MX2011011656A (es) Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento.
CO6150136A2 (es) Combinacion de adapaleno y peroxido de benzoilo para tratar lesiones de acne
ATE516285T1 (de) Dihydropyridinonderivate
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
AR087803A1 (es) N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares